Broward Health Medical Center Becomes First Hospital in Florida to Adopt Advanced Genesis Robotic Technology to Treat Heart R...
07 Abril 2021 - 10:00AM
Stereotaxis (NYSE: STXS), the global leader in innovative robotic
technologies for the treatment of cardiac arrhythmias, announces
that Broward Health Medical Center is establishing a robotic
electrophysiology program to expand access to advanced
minimally-invasive treatment of heart rhythm disorders in Florida.
Broward Health Medical Center will be the only hospital in South
Florida offering robotic technology to treat patients suffering
from arrhythmias and is the first in Florida, and among the first
in the nation, to adopt the latest Genesis Robotic Magnetic
Navigation system.
“The adoption of this advanced robotic
technology further reinforces the commitment Broward Health Medical
Center has toward providing high quality cardiac care for patients
suffering from all types of arrhythmias,” said Ahmed Osman, M.D.,
Medical Director of the Cardiac Electrophysiology Lab. “This
technology helps enhance the reach, precision and stability of the
traditional tools used in ablation therapy, while having inherent
attributes that can increase safety. We are very excited to have
access to this technology for our patients.”
Robotic Magnetic Navigation introduces the
benefits of robotic precision and safety to cardiac ablation, a
common, minimally invasive procedure to treat arrhythmias. Tens of
millions of individuals worldwide suffer from arrhythmias –
abnormal heart rhythms that result when the heart beats too
quickly, too slowly, or with an irregular pattern. When left
untreated, arrhythmias may significantly increase the risk of
stroke, heart failure, and sudden cardiac arrest.
“On the heels of Broward Health Medical Center’s
recent IAC accreditation for electrophysiology, we are excited to
bring this latest technology to our complex arrhythmia program,”
said Heather Havericak, CEO of Broward Health Medical Center.
“Studies suggest that one in four Americans over the age of 40
could develop irregular heartbeats, and over 2.3 million Americans
suffer from atrial fibrillation. The adoption of Robotic Magnetic
Navigation supports our commitment to providing comprehensive
cardiac care for our community and the greater tri-county
area.”
“We are delighted to partner with Broward Health
to help enhance quality of care and access to therapy for patients
in Florida,” said David Fischel, Chairman and CEO of Stereotaxis.
“We applaud their leadership and look forward to supporting their
efforts to build a preeminent heart rhythm program in the
region.”
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. The core components of Stereotaxis’
systems have received regulatory clearance in the United States,
European Union, Japan, Canada, China, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute “forward-looking” statements, usually containing the
words “believe,” “estimate,” “project,” “expect” or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, the Company's ability to continue to manage expenses
and cash burn rate at sustainable levels, continued acceptance of
the Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, competitive
factors, changes resulting from healthcare policy in the United
States, including changes in government reimbursement of
procedures, dependence upon third-party vendors, timing of
regulatory approvals, the impact of the recent coronavirus
(COVID-19) pandemic and our response to it, and other risks
discussed in the Company's periodic and other filings with the
Securities and Exchange Commission. By making these forward-looking
statements, the Company undertakes no obligation to update these
statements for revisions or changes after the date of this release.
There can be no assurance that the Company will recognize revenue
related to its purchase orders and other commitments in any
particular period or at all because some of these purchase orders
and other commitments are subject to contingencies that are outside
of the Company's control. In addition, these orders and commitments
may be revised, modified, delayed or canceled, either by their
express terms, as a result of negotiations, or by overall project
changes or delays.
Stereotaxis Contacts: |
|
Broward Health Medical Center Contacts: |
David L. Fischel |
|
Fara Arca |
Chairman and Chief Executive Officer |
|
Public Relations Specialist |
|
|
754-581-4712 |
Kimberly Peery |
|
farca@browardhealth.org |
Chief Financial Officer |
|
|
|
|
|
314-678-6100 |
|
|
investors@stereotaxis.com |
|
|
Stereotaxis (AMEX:STXS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Stereotaxis (AMEX:STXS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024